Humira in participants with moderate to severe chronic plaque-type psoriasis. Humira in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis. The open labelled study intends to enrol approximately 32 patients in the US. Biosimilar (M923) and Humira in Subjects with Moderate to Severe Chronic Plaque-type Psoriasis.
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects with Rosacea – CLS001-CO-PR-006 December 2015 to Present Psoriasis Sponsor: Promius Pharma, LLC A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days DFD06-CD-005 November 2015 to 2016 Acne Sponsor: Dow Pharmaceutical Sciences, a division of Valeant Pharmaceuticals NA A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris – V01-121A-302 October 2015 to Present Psoriasis Sponsor: Baxalta US, Inc. People who suffer from psoriasis can participate in clinical trials that are focused on testing new and more effective treatments for this skin disorder. Phase 3 Study of M923 and Humira in Subjects With Chronic Plaque-type Psoriasis. Psoriasis. Some information for this disease has been obtained from Bio2RDF, DBPedia and LinkedCT.
Open Label, Randomized Phase 2b Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who do Not Have Favorable Imatinib Response (DASCERN)RecruitingChronic Phase Chronic Myeloid LeukemiaDrug;Drug – Imatinib;DasatinibBristol-Myers Squibb;ICON Clinical Research;PPD;Molecular MD;MultiPharma;Q2 solutions;Donald E. (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis. A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis.
Dawes Fretzin Clinical Research Group » Clinical Studies: 2015 Start Date
In U.S., Phase III trial launched last year. Nature and indication: Tumor necrosis factor (TNF) blocker for rheumatoid arthritis, polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged two years or older; psoriatic arthritis; ankylosing spondylitis; and plaque psoriasis.